Cargando…
Platform Trials to Expedite Drug Development in Alzheimer’s Disease: A Report from the EU/US CTAD Task Force
A diverse range of platforms has been established to increase the efficiency and speed of clinical trials for Alzheimer’s disease (AD). These platforms enable parallel assessment of multiple therapeutics, treatment regimens, or participant groups; use uniform protocols and outcome measures; and may...
Autores principales: | Aisen, P. S., Bateman, R. J., Carrillo, M., Doody, R., Johnson, K., Sims, J. R., Sperling, R., Vellas, B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8136263/ https://www.ncbi.nlm.nih.gov/pubmed/34101788 http://dx.doi.org/10.14283/jpad.2021.21 |
Ejemplares similares
-
Non-Amyloid Approaches to Disease Modification for Alzheimer’s Disease: An EU/US CTAD Task Force Report
por: Gauthier, Serge, et al.
Publicado: (2020) -
Using Digital Tools to Advance Alzheimer’s Drug Trials During a Pandemic: The EU/US CTAD Task Force
por: Kaye, Jeffrey, et al.
Publicado: (2021) -
Tackling a Major Deficiency of Diversity in Alzheimer’s Disease Therapeutic Trials: An CTAD Task Force Report
por: Raman, Rema, et al.
Publicado: (2022) -
Task Force on Reintegration
Publicado: (1991) -
Task Force on Reintegration Guarantees for the pensions of the CERN personnel in the event of the dissolution of the Organization Third Progress Report by the Chairman (Resolution Appendix 1)
Publicado: (1995)